Randomized, open-label delayed-treatment Phase 2 study (n=20) assessing two MDMA-assisted therapy sessions (80 mg initial ±40 mg supplemental; second session may be 120 mg initial ±40 mg) plus preparatory/integrative psychotherapy for adults with generalized social anxiety disorder.
Randomized, open-label delayed treatment (parallel) design with half the sample treated immediately and half after a 16-week wait; primary outcome is LSAS rated by a blinded independent rater.
Intervention comprises 3×90-minute preparatory sessions, 2×8-hour experimental MDMA sessions (supplemental 40 mg 1.5–2 h after initial dose), and 3×90-minute integration sessions; assessments include safety, social anxiety, functional outcomes and mechanistic measures.
Two manualised MDMA-assisted therapy sessions with preparatory and integrative psychotherapy.
Supplemental 40 mg 1.5–2 h after initial; second session initial may be increased to 120 mg if tolerated.
Manualised psychotherapy delivered by two therapists: 3×90-min preparatory sessions, 2×8-h experimental sessions, 3×90-min integrative sessions.
16-week waitlist control then receive same MDMA-assisted therapy protocol.
Participants wait 16 weeks then receive identical MDMA-assisted therapy as experimental arm.